NCT06048133View on ClinicalTrials.gov

Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)

PHASE2RecruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

March 8, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

July 31, 2027

Conditions
Biliary Tract CarcinomaCholangiocarcinomaBile Duct Cancer
Interventions
DRUG

Gemcitabine

Gemcitabine IV: Day 1, 8, 22, and 29 every 42 days

DRUG

Cisplatin

Cisplatin IV: Day 1, 8, 22, and 29 every 42 days of Cycles 1-4 only.

DRUG

Zimberelimab

Zimberelimab IV: Day 1 and 22 every 42 days

DRUG

Quemliclustat

Quemliclustat IV: Day 1, 15, 29 every 42 days

Trial Locations (4)

46202

RECRUITING

Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis

48109

RECRUITING

University of Michigan Health System, Ann Arbor

53705

RECRUITING

University of Wisconsin, Madison

08903

RECRUITING

Rutgers Cancer Institute of New Jersey, New Brunswick

Sponsors
All Listed Sponsors
collaborator

Arcus Biosciences, Inc.

INDUSTRY

collaborator

Gilead Sciences

INDUSTRY

collaborator

University of Wisconsin, Madison

OTHER

lead

Nataliya Uboha

OTHER